stoxline Quote Chart Rank Option Currency Glossary
  
BriaCell Therapeutics Corp. (BCTX)
2.02  -0.12 (-5.61%)    04-19 16:00
Open: 2.175
High: 2.266
Volume: 41,325
  
Pre. Close: 2.14
Low: 2.01
Market Cap: 32(M)
Technical analysis
2024-04-19 5:08:01 PM
Short term     
Mid term     
Targets 6-month :  3.08 1-year :  3.53
Resists First :  2.64 Second :  3.02
Pivot price 2.57
Supports First :  2 Second :  1.67
MAs MA(5) :  2.18 MA(20) :  2.6
MA(100) :  3.77 MA(250) :  5.12
MACD MACD :  -0.3 Signal :  -0.2
%K %D K(14,3) :  9.1 D(3) :  13.5
RSI RSI(14): 29.4
52-week High :  7.59 Low :  2
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BCTX ] has closed above bottom band by 3.4%. Bollinger Bands are 11.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.28 - 2.3 2.3 - 2.32
Low: 1.97 - 1.99 1.99 - 2.01
Close: 1.99 - 2.03 2.03 - 2.06
Company Description

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Headline News

Mon, 25 Mar 2024
Premarket Mover: Briacell Therapeutics Corp (BCTX) Up 5.16% - InvestorsObserver

Thu, 07 Mar 2024
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer ... - GlobeNewswire

Wed, 06 Mar 2024
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC ... - GlobeNewswire

Tue, 27 Feb 2024
BriaCell Provides Update on Alleged Illegal Trading of Public Securities - GlobeNewswire

Tue, 30 Jan 2024
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting - Yahoo Finance

Thu, 30 Nov 2023
Vancouver biotech BriaCell reports tumour shrinkage in clinical trials - Business in Vancouver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 16 (M)
Shares Float 12 (M)
Held by Insiders 12.2 (%)
Held by Institutions 15.4 (%)
Shares Short 678 (K)
Shares Short P.Month 796 (K)
Stock Financials
EPS -0.8
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.5
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -85.5 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.99
Qtrly Earnings Growth 0 %
Operating Cash Flow -31 (M)
Levered Free Cash Flow -20 (M)
Stock Valuations
PE Ratio -2.56
PEG Ratio 0
Price to Book value -4.04
Price to Sales 0
Price to Cash Flow -1.04
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android